Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
Public Deposited- Creator
-
Clemmons, David R.
- Affiliation: School of Medicine, Department of Medicine
-
Miller, Sam
- Other Affiliation: SAM Clinical Research Center
-
Mamputu, Jean-Claude
- Other Affiliation: Theratechnologies Inc.
- Abstract
- Use of growth hormone is associated with side effects, including insulin resistance. The objective of this study was to determine whether tesamorelin, a stabilized growth hormone-releasing hormone analogue, would alter insulin sensitivity or control of diabetes.
- Date of publication
- 2017
- Keyword
- Proteins
- Medicine
- Insulin
- Blood
- Lipids
- Hemoglobin
- HbA1c
- Body Fluids
- Diabetes Mellitus
- Hormones
- Biology and Life Sciences
- Growth Hormone
- Medicine and Health Sciences
- Q
- Metabolic Disorders
- Endocrine Disorders
- Biochemistry
- Type 2 Diabetes
- Cholesterol
- Peptide Hormones
- Science
- R
- Research Article
- Anatomy
- Physiological Processes
- Physiology
- Diagnostic medicine
- DOI
- Identifier
- PMCID: PMC5472315
- Publisher DOI: https://doi.org/10.1371/journal.pone.0179538
- Onescience id: 9d92cbba7b8d8338cbc4253c2e73a0832a19327b
- PMID: 28617838
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- PloS One
- Journal volume
- 12
- Journal issue
- 6
- Page start
- e0179538
- Language
- English
- ISSN
- 1932-6203
Relations
- Parents:
- In Collection:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
PubMedCentral-PMC5472315.pdf | 2017 | Public | Download |